# Study of Apixaban in Patients Receiving Hemodiafiltration

> **NCT04952792** · PHASE2 · COMPLETED · sponsor: **Hospital Universitari de Bellvitge** · enrollment: 11 (actual)

## Conditions studied

- Atrial Fibrillation
- Hemodialysis Complication

## Interventions

- **DRUG:** Apixaban 2.5 milligram Oral Tablet

## Key facts

- **NCT ID:** NCT04952792
- **Lead sponsor:** Hospital Universitari de Bellvitge
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-20
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2023-09-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04952792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04952792, "Study of Apixaban in Patients Receiving Hemodiafiltration". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04952792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*